Efficacy and safety of adalimumab as first-line therapy for treatment-naïve granulomatous lobular mastitis: an exploratory real-world study with propensity score-matching analysis
- DOI
- 10.1007/s10067-026-08431-1
- Published
- 2026-09-26
- Container
- Clinical Rheumatology
- Publisher
- Springer Science and Business Media LLC
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1007/s10067-026-08431-1,
title = {Efficacy and safety of adalimumab as first-line therapy for treatment-naïve granulomatous lobular mastitis: an exploratory real-world study with propensity score-matching analysis},
author = {Yuanhua Lu and Xiaolin Chen and Qianru Chen and Queran Lin and Liling Zhu and Kai Chen},
year = {2026},
journal = {Clinical Rheumatology},
doi = {10.1007/s10067-026-08431-1},
url = {https://doi.org/10.1007/s10067-026-08431-1}
}RIS
TY - JOUR TI - Efficacy and safety of adalimumab as first-line therapy for treatment-naïve granulomatous lobular mastitis: an exploratory real-world study with propensity score-matching analysis AU - Yuanhua Lu AU - Xiaolin Chen AU - Qianru Chen AU - Queran Lin AU - Liling Zhu AU - Kai Chen PY - 2026 JO - Clinical Rheumatology DO - 10.1007/s10067-026-08431-1 UR - https://doi.org/10.1007/s10067-026-08431-1 ER -
APA
Lu, Y., Chen, X., Chen, Q., Lin, Q., Zhu, L., & Chen, K. (2026). Efficacy and safety of adalimumab as first-line therapy for treatment-naïve granulomatous lobular mastitis: an exploratory real-world study with propensity score-matching analysis. Clinical Rheumatology. https://doi.org/10.1007/s10067-026-08431-1
Source records
- crossref · retrieved 2026-09-27T10:06:55.136Z